Utility of cardiac magnetic resonance imaging in troponin-positive chest pain with non-obstructive coronary arteries: literature review

Jinan CY Lee *, Jeanie B Chiang, PP Ng, Boris CK Chow, YW Cheng, CY Wong

ABSTRACT

There is no general consensus on the investigation and subsequent management of patients presenting with acute chest pain and elevated cardiac troponin levels, but with non-obstructive coronary arteries on angiography. Recent technological advances in cardiac magnetic resonance imaging have aided in the understanding of the underlying pathophysiology, allowing accurate diagnosis, prognostic information, and guidance for management in these patients. This article reviews the evidence supporting the usefulness of cardiac magnetic resonance imaging in patients with acute chest pain and elevated cardiac troponin levels, but with non-obstructive coronary arteries, and offers insights into the role and future development of this imaging modality in this disease.

Introduction

Patients presenting with acute coronary syndrome require immediate management with coronary angiography to identify the culprit coronary stenosis.1,2 A small subset of patients with suspected acute coronary syndrome may have angiographically non-obstructive coronary arteries, termed myocardial infarction with non-obstructive coronary arteries (MINOCA).3 Myocardial infarction with non-obstructive coronary arteries is indistinguishable in its clinical presentation from myocardial infarction with coronary artery disease. The normal coronary angiography results pose a dilemma to the managing physician because the underlying aetiology is not immediately apparent. Arriving at a diagnosis is challenging, with significant implications regarding patients’ prognosis, management, and subsequent follow-up.

Myocardial infarction with non-obstructive coronary arteries is a distinct clinical entity with a prevalence of 6% (95% confidence interval [CI], 5%-7%)3 that deserves further meticulous investigation. Despite having non-obstructive coronary arteries, patients with MINOCA have an increased risk of experiencing major cardiovascular events (MACE) including death. Pasupathy et al2 reported 4.7% annual mortality in this group of patients, which is lower than for myocardial infarction with coronary artery disease (6.7%) but much higher than in patients with stable chest pain (0.2% annual mortality).

Causes of MINOCA include acute myocardial infarction (AMI) with spontaneous recanalisation, coronary vasospasm, acute myocarditis, takotsubo cardiomyopathy, and other cardiomyopathies.4 Distinguishing between ischaemic and non-ischaemic aetiologies is crucial in patients presenting with MINOCA, in order to tailor treatments accordingly, such as dual antiplatelet therapy and other secondary preventive medications for myocardial infarction, or heart failure medications for myocarditis or cardiomyopathies.

Cardiac magnetic resonance (CMR) imaging has been increasingly recognised as a first-line imaging modality in the management of patient presenting with MINOCA, to detect the aetiology in a timely manner. High-resolution cardiac images are acquired with tissue characterisation using different MR sequences.

The referral rate of CMR imaging for MINOCA has been low, with only 3% of all eligible patients undergoing further testing by CMR imaging in a retrospective study between 2000 and 2016.5 This is expected to change with the widespread availability and improved image quality of CMR imaging.

The referral rate of CMR imaging for MINOCA has been low, with only 3% of all eligible patients undergoing further testing by CMR imaging in a retrospective study between 2000 and 2016.5 This is expected to change with the widespread availability and improved image quality of CMR imaging.

This review aims to summarise the current evidence regarding the use of CMR imaging in patients presenting with MINOCA, to demonstrate its use in various clinical scenarios, and to identify areas for future research. In particular, we review the optimal timing of CMR imaging. We also examine how CMR imaging may change or confirm the
aetiology, offers prognostic information, and change management strategy.

We reviewed the medical literature in the PubMed database and Google Scholar, using the key terms ‘MINOCA,’ ‘myocardial infarction with non-obstructive coronary arteries,’ ‘troponin-positive acute chest pain,’ ‘non-obstructive coronary arteries,’ ‘cardiac magnetic resonance,’ ‘myocarditis,’ ‘acute myocardial infarction’ and ‘takotsubo cardiomyopathy,’ for studies published up to April 2020. There was no language restriction. Abstracts were reviewed to determine their relevance to the aim of our review. Case reports and papers with unclear or inappropriate statistical methods were excluded. The discussion is based on, but not limited to, the search terms.

**Definition**

According to the European Society of Cardiology working group positional paper, MINOCA is a distinct clinical syndrome characterised by evidence of AMI, but with no evidence of obstructive coronary artery disease on angiography (stenosis <50% diameter in a major epicardial vessel). The term MINOCA refers to ischaemic-related coronary disorders, namely plaque rupture, coronary vasospasm, microvascular dysfunction, distal embolisation, and coronary artery dissection. The American Heart Association states that it is imperative to exclude (a) clinically overt causes for elevated troponin (eg, sepsis, pulmonary embolism), (b) clinically over-looked obstructive disease, and (c) non-ischaemic disease that can mimic myocardial infarction (eg, myocarditis). In clinical practice, however, exclusion of non-ischaemic mechanism is often not straightforward. Elevated cardiac troponin levels signify myocardial injury, but the marker is non-specific for the underlying pathophysiological mechanism. For instance, acute myocarditis and takotsubo cardiomyopathy may present as MINOCA and may sometimes be even more frequent than ischaemic causes. Other non-cardiac causes such as pulmonary embolism or tumour infiltration may also present as MINOCA.

Recently, the term troponin-positive chest pain with non-obstructive coronary arteries (TpNOCA) has been proposed to encompass all patients with ischaemic causes as well as non-ischaemic myocardial disorders and non-cardiac diseases. The Dutch ACS working group suggested that the term MINOCA can be understood as either myocardial infarction or myocardial injury with non-obstructive coronary arteries. Given the numerous underlying possibilities, a detailed diagnostic workup is required for patient presenting with a working diagnosis of MINOCA (Fig 1).

**Cardiac magnetic resonance imaging protocol**

A targeted CMR imaging protocol tailored to the investigation of MINOCA should require no more than 30 to 40 minutes to perform and is feasible in most patients except the most critically ill. The goal of CMR imaging is to assess cardiac motion and characterise myocardial tissue with full left ventricular coverage, to detect myocardial oedema and necrosis for the diagnoses of various disorders, in particular myocarditis and myocardial infarction. Commonly performed CMR imaging sequences are detailed in the online supplementary Appendix.

Myocardial perfusion assessment with pharmacological stress (eg, adenosine) to evaluate reversible perfusion defects is seldom required in patients with MINOCA except for specific indications such as evaluation of ischaemic extent, and may be contra-indicated in patients with AMI. Therefore, this evaluation is not recommended as part of the routine assessment.

**Timing of cardiac magnetic resonance imaging**

Ideally, CMR imaging should be performed as soon as possible to identify oedema and acute wall motion abnormalities. Although CMR imaging is typically performed after 1 to 4 weeks, the diagnostic value for patients with MINOCA improves significantly when performed within 2 weeks of acute presentation. Studies with longer times to CMR imaging generally show lower sensitivity for demonstrating pathology. One study showed that performing CMR imaging within 2 weeks allowed an underlying cause to be identified in a higher percentage of the study population than if CMR imaging was performed after 2 weeks (82% vs 54%, respectively). While the Dutch ACS working group recommends CMR imaging within 4 weeks of presentation, a stricter timeframe of performing CMR imaging within 1 week has been suggested by Ferreira et al.
local practice may depend on availability of imaging resources.

**Differential diagnoses shown in cardiac magnetic resonance in patients presenting with myocardial infarction with non-obstructive coronary arteries**

In a recent study by Dastidar et al, the predominant underlying causes of TpNOCA on CMR imaging in 388 consecutive patients were AMI (25%), myocarditis (25%), and cardiomyopathy (25%), although the median time from clinical presentation to CMR imaging was 37 days. In a recent study by Bhatia et al involving 215 patients, myocarditis (32%) was the most common cause, followed by AMI (22%), cardiomyopathy (20%) and takotsubo cardiomyopathy (9%). The strength of the study was the short time interval from clinical presentation to CMR imaging (median: 3.6 days), which could explain the higher proportion of CMR imaging studies resulting in positive diagnosis and the higher incidence of acute myocarditis and takotsubo cardiomyopathy, in which CMR imaging findings may be transient. Overall, CMR imaging can provide a diagnosis in 30% to 90% of patients, as shown in several studies. However, in some patients, no stressful trigger is identified. The exact pathophysiology of takotsubo cardiomyopathy is unclear; however, some postulate that the underlying pathophysiology is related to microvascular vasoreactivity or hormonal disturbances. Previously considered a benign condition, an arrhythmogenic risk and increased cardiac mortality are increasingly recognised in patients with takotsubo cardiomyopathy. In one study, the prevalence of takotsubo cardiomyopathy in patients undergoing CMR imaging was as high as 27%. Takotsubo cardiomyopathy is diagnosed according to the proposed Mayo Clinic criteria. Because these criteria do not focus on the role of CMR imaging, an update in 2016 by the Heart Failure Association of the European Society of Cardiology endorsed the use of CMR imaging for its excellent depiction of right and left ventricular wall motion abnormalities and myocardial oedema.29
On CMR cine imaging, takotsubo cardiomyopathy has a typical appearance of mid-cavity to apical akinesia with sparing of basal segments. Although these findings can also be seen in echocardiography and left ventricular angiography, the ability of CMR imaging to assess areas of myocardial oedema and late gadolinium enhancement (LGE), as well as to exclude alternative diagnoses (eg, AMI), makes this an important modality when assessing takotsubo cardiomyopathy. Myocardial oedema (as evidenced using short tau inversion recovery or T2 mapping techniques) on CMR images correlates with acute myocardial inflammation and electrographic pattern/repolarisation indices in takotsubo cardiomyopathy. The presence of LGE is believed to be transient rather than irreversible. Another study showed that LGE in the acute phase was associated with acute cardiogenic shock, higher peak creatine kinase levels, and delayed recovery. Neil et al found that the extent of the increase in T2-weighted signal intensity correlated with myocardial strain and the release of both catecholamines and N-terminal pro-B-type natriuretic peptide.

Although no specific treatment is currently available, and spontaneous and complete recovery is often expected, Dastidar et al showed that mortality in patients with takotsubo cardiomyopathy can be as high as 15% over 3 years, rejecting the notion that this is an entirely benign condition. More studies exploring the underlying mechanism and management strategy for takotsubo cardiomyopathy are required.

**Acute myocarditis**

Acute myocarditis (Fig 3) accounts for 15% to 81% of CMR imaging diagnoses in multiple studies. There are myriad causes of acute myocarditis, including viral infections, autoimmune disease, and toxins. Patients’ clinical courses vary and range from complete recovery to progression to chronic myocarditis and dilated cardiomyopathy. Endomyocardial biopsy remains the gold standard for diagnosing acute myocarditis, although its use...
is declining because of its invasiveness and the possibility of sampling error. A previous study has validated CMR imaging results compared with endomyocardial biopsy; CMR-guided endomyocardial biopsy can improve the diagnostic rate.

The CMR diagnosis of acute myocarditis has been made according to the original Lake Louise criteria, which were established in 2009. These criteria are based on the presence of at least two of three CMR imaging findings: myocardial oedema on T2-weighted images, hyperaemia and capillary leak on EGE, and fibrosis/necrosis on LGE. These criteria have a diagnostic accuracy of 78% for acute myocarditis. However, co-existing skeletal inflammation may lead to false-negative results in T2 short tau inversion recovery/early gadolinium enhancement images. With the development of parametric mapping, T1 mapping can establish the diagnosis of myocarditis, even without contrast injection for LGE. T1 mapping as an individual parameter was found to have superior diagnostic performance for detecting myocarditis compared with T2-weighted oedema imaging. More recently, a Journal of the American College of Cardiology scientific expert panel updated the use of CMR imaging in myocarditis to include parametric mapping based on at least one T2-based criterion (global or regional increase in myocardial T2 relaxation time or an increased signal intensity in T2-weighted CMR images), with at least one T1-based criterion (increased myocardial T1, extracellular volume or LGE). The inclusion of global or regional T1 or T2 myocardial values is expected to improve the diagnostic accuracy of CMR imaging compared with the original Lake Louise criteria. Extracellular volume measurements can also be obtained after contrast administration, adjusting for individual variation in the haematocrit value that may affect the result. The presence of both T2- and T1-based criteria is diagnostic of acute myocardial inflammation, while having only one criterion may still support the diagnosis in an appropriate clinical scenario, albeit with less specificity. The updated Lake Louise criteria have been validated by Luetkens et al to have better sensitivity than the original Lake Louise criteria (88% vs 73%, P=0.031), with a similar high specificity of 96%.

In addition to diagnosing acute myocarditis, CMR imaging findings have prognostic implications and can help guide patient management. Grun et al indicated that LGE was the best independent

FIG 3. Magnetic resonance imaging findings in acute myocarditis. T2-weighted imaging in (a) short axis view and (b) four-chamber view showing evidence of myocardial oedema (white arrows) in the lateral left ventricle. (c) Four-chamber early gadolinium enhancement images showing evidence of myocardial hyperaemia (black arrow). (d) Late gadolinium enhancement images showing epicardial enhancement (black arrowheads) compatible with acute myocarditis.
predictor of all-cause mortality and of cardiac mortality in 222 consecutive patients with biopsy-proven viral myocarditis. A recent systematic review and meta-analysis by Yang et al. showed that LGE in patients with myocarditis or suspected myocarditis was significantly associated with MACE (pooled odds ratio=4.57, 95% confidence interval [CI]=2.18-9.59; P<0.001), regardless of the left ventricular ejection fraction. A study by Grani et al. showed that both the pattern and extent of LGE were significantly associated with MACE. Aquaro et al. showed that the prognostic value of CMR imaging extends beyond the acute phase, with the presence of LGE with oedema at 6 months being an independent predictor of adverse cardiac events and associated with worse prognosis, especially mid-wall septal patterns in LGE.

More studies are required to determine whether CMR imaging can help differentiate the subtypes of myocarditis (viral, eosinophilic, autoimmune and giant cell myocarditis).

**Acute myocardial infarction**

Acute myocardial infarction (Fig 4) was either the most common or second most common aetiology detected by CMR imaging in previous studies, ranging from 11% to 26%.

The underlying pathophysiological mechanisms included plaque disruption with spontaneous recanalisation, distal embolisation, coronary vasospasm, dissection, or distal small branch disease. On CMR imaging, a classic subendocardial or transmural LGE pattern corresponding to the coronary artery territory, with or without microvascular obstruction, is diagnostic of myocardial infarction. If an infarct is seen, it is essential to review the coronary angiographic images for subtle missed obstructive lesions or coronary artery dissection, and to rule out vasospasm or distal embolisation. Further investigations may depend on clinical suspicion and local practice, and may include intravascular imaging such as optical coherence tomography and intravascular ultrasonography for plaque assessment, provocative tests for coronary vasospasm, echocardiography to identify an embolic source (eg, patent foramen ovale) and thrombophilia screening for hypercoagulable disorders. In Asian populations, vasospastic angina is particularly common and should be carefully managed. Drugs such as cocaine are well-documented causes of coronary vasospasm and careful elucidation of history is required.

In addition to providing a diagnosis, CMR imaging can also assess myocardial oedema and myocardium at risk in the acute phase to calculate the salvageable area, as well as to assess complications of AMI, such as pseudoaneurysms or intra-cardiac thrombus. Both the presence of a scar and the quantifiable extent of the infarct on LGE have been shown to carry prognostic significance in AMI for predicting morbidity and mortality. The presence of microvascular obstruction is also associated with a worse prognosis. T1 mapping and extracellular volume measurement may be able to differentiate between acute and chronic myocardial infarction.

**Non-ischaemic cardiomyopathies**

Hypertrophic cardiomyopathy and dilated cardiomyopathy are the most common forms of non-ischaemic cardiomyopathy presenting with MINOCA (Fig 5). These cardiomyopathies can be diagnosed using CMR imaging according to their morphology and LGE patterns. The prevalence of non-ischaemic cardiomyopathies in MINOCA varies widely in the literature, and it is unclear whether affected patients were excluded in some studies. Bhatia et al. showed the highest prevalence of cardiomyopathy among studies that included affected patients, with a prevalence of 20%, making cardiomyopathy the third most common aetiology in MINOCA. A recent study by Dastidar et al. showed that cardiomyopathy had the worst prognosis among all diagnoses.

A systematic review by Kuruvilla et al. showed that patients with non-ischaemic cardiomyopathy with LGE had greater all-cause mortality compared with patients without LGE (odds ratio=3.27; 95% CI=1.94-5.51; P<0.0001). In hypertrophic cardiomyopathy, a meta-analysis showed that the presence of LGE was associated with an increased risk of sudden cardiac death, heart failure, and cardiovascular mortality and that the extent of LGE was also strongly associated with the risk of sudden cardiac death, suggesting that quantifying LGE is an important tool for risk stratification.

The growing use of parametric mapping will no doubt further enhance the diagnostic capability of CMR imaging in non-ischaemic cardiomyopathies.

**Normal/inconclusive cardiac magnetic resonance**

Cardiac magnetic resonance may sometimes not reveal a specific diagnosis, the proportion of which depends on the timing of CMR imaging as well as patients’ demographics. Patients with negative CMR imaging findings typically have a lower troponin level. Occasionally, an infarct may be too small to be visualised by conventional LGE sequences. Negative CMR imaging findings do not exclude MINOCA. Regardless of whether the underlying cause is identified, the absence of positive CMR imaging findings is associated with a better prognosis.

**Managing patients with myocardial infarction with non-obstructive coronary arteries**

Limited guidelines exist regarding the current recommended management of patients with...
MINOCA, and the management algorithm differs in different centres. Treatment obviously depends on the underlying diagnosis, if identified. In patients without an apparent cause, even by CMR imaging, evidence-based therapies are lacking. Recently, aspirin, statins and calcium channel blockers have been proposed as routine medical treatment in patients with no clear aetiology for elevated troponin on CMR images, to potentially treat underlying thromboembolism, coronary plaque disruption and coronary artery vasospasm.6 The evidence for the use of beta-blocker is conflicting.59,60 The confirmation of the benefits of these therapies would require a multicentre randomised controlled trial.

Questions to be addressed

There is a distinct lack of published studies evaluating patients of Asian descent with MINOCA, for whom the local disease spectrum with CMR imaging and the prognostic significance may differ from studies evaluating patients from Western countries, because of differences in the underlying risk factors. It is still unclear in current studies whether performing CMR imaging improves patient outcomes regarding shortening hospital stay, preventing re-admission and lowering MACE and mortality rates. This hypothesis requires validation in further studies in a large patient cohort, with longer follow-up of clinical outcomes. Further studies are also needed to evaluate the relationship between troponin and the extent of LGE, the optimal management pathway and secondary prevention, as well as the role of long-term imaging surveillance to guide management in patients with MINOCA.

Future directions

With the emergence of novel parametric mapping techniques, namely T1/T2 mapping and extracellular volume measurement, the sensitivity of CMR imaging is expected to improve, as most previous studies did not use T1 and T2 mapping. The optimal mapping techniques and post-processing methods are still being determined,61 after which the capability of CMR imaging for diagnosis and prognostication can be further enhanced, providing a better understanding of the underlying pathophysiology in MINOCA. A gadolinium-free or LGE-free protocol combining T2-based CMR imaging with T1 mapping holds significant promise, especially for patients contra-indicated for gadolinium, but further studies are required before this approach can be routinely implemented. Further developments in CMR imaging techniques, such as three-dimensional free-breathing high-resolution LGE,58 can lead to a higher rate of definitive myocardial LGE evaluation, thereby reducing the false-negative rate in MINOCA diagnosis. Dedicated rapid CMR imaging protocols or compressed sensing cine can shorten scanning times and permit acquiring diagnostic CMR imaging information even in critically ill patients.
In conclusion, troponin-positive chest pain with non-obstructive coronary arteries should be recognised as a distinct clinical entity that deserves an active search for the underlying cause and a detailed management plan. The absence of obstructive disease on angiography does not necessarily exclude AMI. When performed early in the disease course, CMR imaging is the ideal non-invasive adjunct to conventional cardiac investigations in patients presenting as MINOCA. Cardiac magnetic resonance should be routinely used in these patients for diagnosis and risk stratification to guide further therapy.

**Author contributions**

Concept or design: JCY Lee.
Acquisition of data: All authors.
Analysis or interpretation of data: JCY Lee, JB Chiang, PP Ng, BCK Chow.
Drafting of the manuscript: JCY Lee, JB Chiang, YW Cheng, CY Wong.
Critical revision of the manuscript for important intellectual content: JCY Lee, YW Cheng, CY Wong.

All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.

**Conflicts of interest**
The authors have disclosed no conflicts of interest.

**Funding/support**
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Ethics approval**
The patients were treated in accordance with the Declaration of Helsinki. The patients provided written informed consent for all procedures.

**References**

3. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF.


